Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 514Specimen Handling 384Carboplatin 372Magnetic Resonance Spectroscopy 337Cisplatin 327Nivolumab 301Cyclophosphamide 297Radiotherapy 255Paclitaxel 255Biopsy 237Gemcitabine 229Bevacizumab 212Dexamethasone 168durvalumab 162Oxaliplatin 159Capecitabine 154Rituximab 153Fluorouracil 148venetoclax 143atezolizumab 142Drug Therapy 140Docetaxel 140Etoposide 139Doxorubicin 132Ipilimumab 124Lenalidomide 119Radiosurgery 118Prednisone 116Leucovorin 112fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × CYT003-QbG10 × 1 year × Clear all
NCT05445609 2025-09-19

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Emory University

Phase 2 Suspended
10 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡